TNFRSF17 and plasma cell myeloma: The FDA has approved six CAR T products targeting CD19 for the treatment of R/R diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL), and two targeting the B-cell maturation antigen (BCMA) for the treatment of multiple myeloma (MM) [28,31].